T he subset of patients with obstructive sleep apnea (OSA) who have chronic daytime hypercapnia (PaCO 2 > 45 mm Hg) experience a lower quality of life, 1, 2 have greater healthcare expenses, 3 and have a higher risk of pulmonary hypertension. 4, 5 Hypercapnia is associated with a 4-fold increase in mortality among the severely obese after adjusting for age and body mass index (BMI). 6, 7 Although the estimated prevalence of chronic daytime hypercapnia in patients with OSA varies widely, from 10% to 38% [8] [9] [10] [11] [12] (35% in our clinic population), the prevalence may increase, at least in the United States, in parallel with the rising incidence of obesity. 12, 13 The optimal management of patients with hypercapnia associated with OSA remains uncertain despite several small studies reporting improvement of hypercapnia with positive airway pressure (PAP) therapy. [14] [15] [16] [17] [18] [19] The largest of these studies had a sample size of 23 patients, 17 and none of them measured the effect of average daily use of PAP on the improvement of hypercapnia.
We performed a retrospective cohort study of 75 patients with OSA and chronic daytime hypercapnia to describe the effect of adherence with PAP therapy on PaCO 2 and PaO 2 and to identify factors that modify response to therapy.
METHODS

Study Population
We assembled the cohort by first identifying patients with OSA and chronic daytime hypercapnia who received PAP therapy (n=169). All patients were followed at the sleep medicine clinic of a large public urban teaching hospital between April 2000 and April 2004. Our inclusion criteria were age above 18 years, a stable daytime PaCO 2 above 45 mm Hg with a pH less than 7.45 (without evidence of acute respiratory acidosis or metabolic alkalosis) measured in an ambulatory setting, apnea-hypopnea index (AHI) above 10 per hour, and therapy with a PAP machine equipped with a downloadable memory card. We excluded patients if their pretreatment arterial blood gases were measured during a hospitalization or more than a year before starting therapy with PAP or if their posttreatment arterial blood gases were measured more than 2 years after starting therapy. We also excluded patients lack-
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Data Collected
Patients presenting to our sleep clinic for the suspicion of sleep apnea had the following data routinely collected: demographics, symptoms of OSA, comorbid medical disorders, Epworth Sleepiness Scale score, 20 Beck Depression Inventory score, 21 pulmonary function test (PFT), and results of polysomnography and PAP titration. PFTs were ordered by internists or pulmonologists for evaluation of dyspnea or to determine the need for home oxygen therapy. Arterial blood samples were drawn from the radial artery with the patients sitting for 20 minutes and breathing room air. We recorded the results of arterial blood gas analysis performed before (first) and after at least 30 days of therapy with PAP (second). All arterial blood samples were analyzed by cooximetry (ABL 725 System, Radiometer, Denmark). PFTs included spirometry and measurement of lung volume (SensorMedics, Loma Linda, CA) and were performed according to the American Thoracic Society standards. 22 Weight was measured in the sleep laboratory on a scale with maximum limit of 340 kg (Scale-Tronix, Wheaton, IL).
Polysomnography and PAP Titration
Polysomnograms were recorded online and monitored continuously in the laboratory using a 16-channel system (Sandman Elite version 7.0, Ontario, Canada). The polysomnograms were scored by experienced registered polysomnography technicians according to standard practices. 23, 24 Interscorer agreement in our laboratory is routinely monitored and is 90% or higher. Titrations started in continuous PAP (CPAP) mode, and supplemental oxygen or bilevel PAP was considered if CPAP had eliminated all respiratory events and the SaO 2 remained below 88%. A split-night protocol was performed in 92% of our patients; titration of PAP was initiated after 3 hours of baseline sleep in patients who exhibited repetitive episodes of obstructive respiratory events with an AHI above 20 per hour.
Adherence with PAP Therapy
Our main predictor variable was adherence with PAP therapy.
We measured adherence by calculating the mean number of hours per day a patient used PAP at the prescribed pressure during the 30 days before the second (follow-up) measurement of arterial blood gases. Daily use at the prescribed pressure was monitored by Smartcard technology (Respironics Encore ® Pro Smartcard ™ , Murrysville, PA). We selected the 30-day period before the second measurement of arterial blood gases because all patients were on therapy for at least 30 days and because there was no significant difference in model results when we explored 60-and 90-day periods.
This study was approved by the hospital's Institutional Review Board.
Statistical Analysis
We compared the characteristics of the study sample with the group of patients who were excluded from the analyses to assess whether our sample was representative of the entire population of patients with hypercapnia and OSA seen in our clinic. We used χ 2 , t-tests, and Mann-Whitney tests where appropriate.
We used general linear models to assess the effect of predictors on the change in PaCO 2 , our primary outcome. The same modeling strategy was used to evaluate the change in PaO 2 , our secondary outcome. Groups of potential predictors were entered into the model and tested using a hierarchical strategy: first, the baseline blood gas values were entered and tested; second, demographic variables; third, baseline clinical data, including PFT and polysomnography results; and, finally, adherence with PAP therapy was added and tested. Hypothesizing that adherence might have a nonlinear relationship with the change in PaCO 2 because of a likely ceiling or plateau effect, we tested whether quadratic or cubic terms for adherence were also significant. At each step, we retained those variables that remained significant at the 5% level. We modeled the change in PaCO 2 while controlling for the baseline PaCO 2 value because controlling for the baseline value makes the analysis less subject to bias from regression to the mean and usually yields more-precise estimates. 25 We used a bootstrap resampling procedure to internally validate the 2 predictive models and generate confidence intervals for the effect size of significant predictors. 26 All analyses were conducted using the statistical software of SPSS, version 12 (SPSS, Inc, Chicago, IL) or STATA, version 8 (StataCorp, College Station, TX).
RESULTS
Comparison of Patients With Hypercapnia Included in the Analysis With Patients Who Were Excluded
Among the 169 subjects with hypercapnia and OSA who were treated with PAP therapy, 94 met 1 of the exclusion criteria (Table  1) , leaving 75 subjects eligible for study. The 75 study subjects were similar to the 94 excluded subjects on the 38 variables measured at baseline, except for 3: study subjects spent more time on PAP titration (363 vs 240 minutes, p < .001), subjects were more likely to be prescribed nocturnal oxygen (37% vs 20%, p = .01), and a higher percentage of subjects received bilevel PAP (20% vs 9%, p = .03) ( Table 2 ). For the entire cohort of 75 patients, the first measurement of arterial blood gases was performed at a median of 84 days (interquartile range 32-162 days) before initiating PAP therapy. The second measurement of arterial blood gases 58 was performed at a median of 91 days (interquartile range 42-253 days) after initiating therapy.
Adherence with PAP Therapy and Change in PaCO 2
For the 34 patients (45%) whose adherence was more than 4.5 hours per day, the average drop in PaCO 2 was 7.7±5 mm Hg, compared with 2.4±4 mm Hg in patients whose adherence was less than 4.5 hours per day (p < .001). The second PaCO 2 normalized (< 45 mm Hg) in 34% of patients with adherence of more than 4.5 hours per day compared with 17% of patients with adherence less than 4.5 hours per day (p = .001). For the entire cohort, the PaCO 2 decreased from 54±7 mm Hg to 49±7 mm Hg (p < .001).
Using multivariable general linear modeling, we identified 4 variables that independently predicted the change in PaCO 2 and explained 70% of its variance: (1) average daily use of PAP therapy (adherence), (2) adherence squared, (3) percentage of predicted forced expiratory volume at 1 second (FEV 1 ), and (4) first PaCO 2 (Table 3, Figure 1 ). The significance of the quadratic term-adherence squared-indicates that the relationship between adherence and change in PaCO 2 is nonlinear, with a plateau in improvement after 7 hours of daily PAP therapy. Thus, an average use of 2 hours daily produces a decline of 3 mm Hg in PaCO 2 , 4 hours daily produces a decline of 6 mm Hg, and more than 7 hours of daily use produces a decline of 8 mm Hg.
The change in PaCO 2 was unrelated to age, sex, race, BMI, change in weight, presence of obstructive airways disease or other comorbidities, PFT variables other than FEV 1 percentage of predicted, symptoms of OSA, AHI, AHI on prescribed pressure, arousal index, or lowest oxygen saturation during polysomnography. The type of PAP (bilevel or continuous), use of nocturnal oxygen, and total duration of therapy had no impact on the change in PaCO 2 . Results did not differ significantly if we calculated adherence using other periods (for example, the 60-day period preceding the last blood gas measurement) or if we used the patient's cumulative use of PAP. 
Adherence With PAP Therapy and Change in PaO 2
For the entire cohort, the PaO 2 increased from 59±11 mm Hg to 64±11 mm Hg (p < .001). For the 34 patients (45%) whose adherence was more than 4.5 hours per day, the average increase in PaO 2 was 9.2±11 mm Hg compared with 1.8±9 mm Hg in less-adherent patients (p < .001). In adherent patients, the proportion of patients with a PaO 2 of less than 55 mm Hg decreased from 30% to 6% (p = .02) in contrast to an insignificant decrease of 34% to 32% in less-adherent patients (p = .01 for comparison between groups).
The change in PaO 2 was independently predicted by adherence, adherence squared, first PaCO 2 , baseline PaO 2 , and age (r 2 =0.48) ( Table 4) . Based on the model, the change in PaO 2 reached a plateau at approximately 4.5 hours of average daily therapy with PAP. The change in PaO 2 was unrelated to sex, race, BMI, change in weight, presence of obstructive airways disease or other comorbidities, PFT variables, symptoms, AHI, arousal index, or the lowest oxygen saturation during polysomnography. The type of PAP (bilevel or continuous), use of nocturnal oxygen, and duration of therapy also had no impact on the change in PaO 2 .
Failure to Improve Hypercapnia Despite Adequate Adherence to Therapy
Among the 34 patients who used PAP for at least 4.5 hours per day, 8 patients (23%) did not have a significant improvement in their PaCO 2 -decrease in PaCO 2 of less than 4 mm Hg. These nonresponders had less-severe disease, represented by a lower AHI, compared with responders (44±45 vs 86±47 per hour, p = .03). Nonresponders and responders were similar in age, race, sex, BMI, final AHI on prescribed pressure, time spent during polysomnography on titration of PAP, type of PAP therapy (continuous vs bilevel), FEV 1 percentage of predicted, percentage of predicted forced vital capacity (FVC), FEV 1 /FVC ratio, baseline PaCO 2 and PaO 2 , and adherence. Mean adherence with PAP therapy was 7.2±2.1 hours per day for nonresponders vs 6.0±1.7 hours per day for responders (p = .1).
DISCUSSION
We found that among hypercapnic patients with OSA, the magnitude of improvements in PaCO 2 and PaO 2 were directly related to adherence with PAP therapy but unrelated to BMI, change in weight, pulmonary function parameters (except percentage of predicted FEV 1 ), duration of therapy, type of PAP therapy (bilevel vs CPAP), or polysomnography characteristics.
In this cohort, the only modifiable determinant of the change in PaCO 2 and PaO 2 was adherence with PAP therapy. Initially, the PaCO 2 dropped by 1.84 mm Hg for each hour of daily therapy with PAP. The beneficial effects of PAP therapy on PaCO 2 plateaued after 7 hours of average daily use, and the effect on PaO 2 plateaued after 4.5 hours, hence the significance of the "adherence squared" term. The magnitude of benefit was greatest among patients with the highest baseline PaCO 2 . While some of the improvement might be a regression to the mean, patients with the highest baseline PaCO 2 were probably more responsive to therapy. Patients with a higher percentage of predicted FEV 1 experienced a greater reduction in PaCO 2 . Percentage of predicted FEV 1 was, however, weaker than adherence with therapy in predicting change in PaCO 2 . For example, in 2 patients with identical adherence with therapy, the patient with an FEV 1 of 70% of predicted will experience a drop in PaCO 2 that will be only 1.6 mm Hg higher than the patient with an FEV 1 of 50% of predicted (0.08 mm Hg per 1% of increase in percentage of predicted FEV 1 ).
Although morbid obesity, obstructive ventilatory defects, restrictive ventilatory defects, daytime hypoxemia, and severe and prolonged nocturnal oxygen desaturation have been proposed as mechanisms behind the pathogenesis of hypercapnia in patients with OSA, none of these variables were related to the change in PaCO 2 in our model. [8] [9] [10] 19, [27] [28] [29] [30] [31] [32] [33] It is possible that we were unable to demonstrate a relationship between BMI or change in BMI and the change in PaCO 2 because our cohort was homogeneously obese and few patients lost weight between the 2 blood-gas measurements.
The PaO 2 initially improved by approximately 3 mm Hg for each hour of daily therapy with PAP but quickly plateaued after 4.5 hours. With this degree of improvement in oxygenation, daytime home oxygen therapy can be discontinued for many patients.
The number of days patients had the PAP machine and the cumulative use of PAP beyond the last 30 days did not predict the change in PaCO 2 . These findings reflect the importance of the most recent use of PAP therapy on PaCO 2 and that the full benefits of therapy-at least regarding arterial blood gases-will be realized in 1 month. This finding is consistent with prior reports in which PaCO 2 normalized after 2 weeks of therapy with either noninvasive ventilation or tracheostomy. 16, 19 In both reports, however, the baseline PaCO 2 (47-49 mm Hg), BMI, or AHI were lower than in our cohort. } 34% (19-53%) The 23 patients in the retrospective study by Berger et al 17 are the most comparable with ours in terms of BMI, PaCO 2 , and AHI. Adherence with PAP therapy in their study was assessed subjectively. The PaCO 2 dropped 10 mm Hg after a period of therapy that ranged from 4 days to 7 years. The PaCO 2 did not change in patients who reported nonadherence and dropped by 16 mm Hg in patients who reported adherence with therapy. This study was limited by a wide range of follow-up period, subjective assessment of adherence, significant weight loss in adherent patients, and the large proportion of patients who had a tracheostomy (one third). We avoided these limitations by using more stringent, though arbitrary, inclusion criteria, such as excluding patients who lacked objective adherence data, had post-treatment measurement of arterial blood gases performed beyond 2 years of therapy, or underwent tracheostomy. Our cohort had a median percentage weight loss of 1.0% (interquartile range, 1%, 3.9%) between the measurements of the 2 arterial blood gases. The maximum weight loss was 16%. Peppard et al 34 reported that a 10% weight loss predicted a 26% decrease in the AHI. We believe that the percentage of weight loss in our cohort was clinically inconsequential. In the general linear model analysis, the change in weight was unimportant in predicting the change in PaCO 2 .
Our study has several limitations. First, it was a retrospective analysis that, by design, allows the introduction of selection bias. However, we obtained data on all 169 patients with hypercapnia and OSA seen in our clinic during a 4-year period and documented the similarity between excluded and included patients, supporting the assumption that this was a representative sample without significant selection bias. Second, multiple measurements of arterial blood gases were not available for more precise estimates of PaCO 2 and PaO 2 at baseline and follow-up. Third, there was significant variability in the timing of arterial blood gases before and after therapy. Fourth, we included some patients with obstructive airways disease; however, their inclusion enabled us to develop a more inclusive and generalizable predictive model. Finally, the patients served at our clinic are predominantly from an uninsured, urban, minority population; however, it is just this population that appears to be at highest risk of developing severe OSA. [35] [36] [37] [38] 
Implications in the Pathogenesis of Hypercapnia in Patients With OSA
The improvement in hypercapnia in patients adherent to PAP therapy was neither universal nor complete, as demonstrated by 2 patient subgroups. In the first subgroup, the PaCO 2 did not change in 8 patients with a baseline PaCO 2 of 51 mm Hg despite 7 hours of daily therapy. In the second subgroup, the PaCO 2 decreased from 54±7 mm Hg to 45±4 mm Hg in 26 patients who used PAP for 6 hours daily; however, the PaCO 2 remained elevated (>45 mm Hg) in 11 of them. We hypothesize that, in the first subgroup, OSA did not play a role in the pathogenesis of hypercapnia. This hypothesis can explain why these nonresponders had lower AHIs, suggesting that obesity was the main mechanism for hypercapnia in this subgroup. Morbid obesity can contribute to daytime hypercapnia through mechanisms other than severe OSA. For example, it has been suggested that hyperleptinemia with leptin resistance plays a role in the pathogenesis of hypercapnia. 39, 40 The incomplete response to PAP therapy in the second subgroup suggests that, in addition to obesity, OSA plays a mechanistic role in the development of hypercapnia. It is possible that prolonged untreated OSA resets the central chemoreceptors and thereby makes the response to therapy incomplete. [41] [42] [43] The resetting of central chemoreceptors might be partially reversible within 30 days of therapy. It is important to emphasize that our definition of nonresponders is arbitrary and might miss small genuine response in cases of mild hypercapnia.
In summary, the improvements in PaO 2 and PaCO 2 were directly related to adherence with PAP therapy and plateaued after 5 to 7 hours of daily use, respectively. Hypercapnia did not improve in a fourth of patients adherent to therapy. Further research is needed to explain this phenomenon and to evaluate alternative therapies in this group of patients. Patients can overestimate their adherence with PAP therapy [44] [45] [46] ; therefore, clinicians should rely on objective evidence of adherence. Physicians could provide more effective care if they promptly recognize and address obstacles to poor adherence.
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